FDA Finalizes Labeling Guidance for Prescription Drug Apps and Software

by admin
FDA Finalizes Labeling Guidance for Prescription Drug Apps and Software

The FDA finalized guidance treating content from drug companies’ apps as drug labeling, replacing its 2023 draft on Oct. 21, 2026.

The US Food and Drug Administration (FDA) has finalized guidance on apps and software that drug companies give out with prescription medicines. It treats what the software shows patients and doctors as drug labeling, and comments stay open at any time.

The FDA announced the final guidance in the Federal Register on Oct. 21, 2026, ending a process that began with a draft on Sept. 19, 20231. It covers drug companies, called sponsors, that distribute software for use with prescription drugs or drug-led drug-device combination products1. The guidance is nonbinding, and the public may comment on it at any time under docket FDA-2023-D-24822.

At a glanceDetails
What was publishedFinal guidance for industry, "Regulatory Considerations for Prescription Drug Use-Related Software"
Published on21 October 2026 (posted by FDA on 20 October 2026)
Who must complyDrug sponsors that distribute software for use with their prescription drugs
Feedback deadline / Effective dateComments accepted at any time. No fixed compliance date is set
Final rules / Next milestoneGuidance is final. It replaces the September 2023 draft

What is drug use-related software, and why does it matter?

The guidance covers software that a drug sponsor, or a developer working for it, distributes3. The software must produce output that supplements, explains, or relates to one of the sponsor’s drugs3. This applies whether or not the software is also regulated as a medical device1.

What the guidance covers

DimensionProvision
Who it coversSoftware distributed by or for a drug sponsor
What it coversOutput that supplements, explains or relates to the sponsor’s drugs
How output is treatedAs a type of prescription drug labeling
Outside scopeSoftware not distributed by or for a sponsor

Output means any content the software shows an end user, such as a patient, caregiver or health care practitioner1. The FDA considers that output a type of prescription drug labeling1. That brings app screens and messages under the same truthfulness rules that apply to printed drug information.

The FDA lists possible uses such as tracking doses, giving individual dosing advice, predicting treatment response and managing side effects3. Software made by an outside developer, not distributed by or for a sponsor, falls outside the guidance3. Software whose content is purely about a disease, not a specific drug, is generally also outside it3.

How the FDA sorts software output

The agency splits drug labeling into two groups3. FDA-required labeling is reviewed and approved as part of a drug’s marketing application3. Promotional labeling is generally everything else3.

To decide which group an app’s output belongs in, the FDA will weigh three questions3.

Question the FDA asksWhy it matters
Is the software essential to safe and effective drug use?It may need describing in the prescribing information3
Does evidence show a meaningful improvement in a clinical outcome?FDA decides this based on evidence the sponsor provides3
Does the software rely on data from a device?This marks it as device-connected rather than standalone3

Device-connected functions use data sent from the device part of a combination product3. Standalone functions are all the rest, such as features that rely on data typed in by users3.

What changed from the 2023 draft

The FDA says it considered public comments on the draft before finalizing1. The final version makes four main changes1.

  • It clarifies how the rules apply to standalone software functions1.
  • It adds a decision tree to guide sponsors through labeling choices1.
  • It gives example wording for the prescribing information for both device-connected and standalone software1.
  • It recommends a statement in the prescribing information when device-connected software shows no meaningful clinical improvement1.

The prescribing information is the official drug summary for doctors. It must hold the essential scientific facts needed for safe and effective use3. It must also be accurate, up to date, and not promotional or misleading3.

What changes for drug sponsors

The guidance explains how the prescribing information should describe software functions3. It also explains when and how sponsors should submit software output to the FDA for review1. Sponsors are encouraged to discuss planned software functions with the relevant FDA review division3.

Promotional output carries its own duties. Promotional labeling must be truthful, balanced on benefits and risks, and reveal material facts3. Firms that send out promotional materials must also submit them to the FDA on Form FDA 22533.

The guidance does not change device rules3. Some software functions may still meet the legal definition of a medical device and face device requirements3.

Legal status and enforcement

FDA guidance documents do not create legally enforceable duties on their own3. Firms may use another approach if it meets the applicable laws and regulations1. The FDA found the action is neither a regulatory nor a deregulatory action under Executive Order 141921.

From draft to final

19 Sep 2023 Draft guidance issued
20 Oct 2026 Final guidance posted
21 Oct 2026 Federal Register notice

The underlying law still bites. A drug shipped across state lines with false or misleading labeling is misbranded under the Federal Food, Drug, and Cosmetic Act3. Because app output counts as labeling, that standard now clearly reaches software content.

Key dateWhat happens
19 September 2023FDA issues the draft guidance1
20 October 2026FDA posts the final guidance2
21 October 2026Federal Register notice published1

Key terms in plain words

TermMeaning
SponsorA company that seeks or holds FDA approval for a drug
End-user outputAny content an app shows a patient, caregiver or doctor
Prescribing informationThe official FDA-approved drug summary for health professionals
Combination productA product that contains both a drug and a device part
Standalone softwareSoftware features not fed by data from a device
MisbrandedSold with false or misleading labeling, which breaks federal law

The guidance was announced on Oct. 21, 2026, and comments remain open at any time under docket FDA-2023-D-24822.

Sources

  1. ↩ Federal Register :: Regulatory Considerations for Prescription Drug Use-Related Software; Guidance for Industry; Availability https://www.federalregister.gov/documents/2026/10/21/2026-21516/regulatory-considerations-for-prescription-drug-use-related-software-guidance-for-industry
  2. ↩ Regulatory Considerations for Prescription Drug Use-Related Software | FDA https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-prescription-drug-use-related-software
  3. ↩ Regulatory Considerations for Prescription Drug Use- Related Software https://www.fda.gov/media/172165/download

You may also like